Market Place
Sourcing Support
Xilio Therapeutics to Present XTX601 Data at the AACR Meeting
17 Apr 2026 //
FIRSTWORD PHARMA
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Rules
03 Apr 2026 //
GLOBENEWSWIRE
Xilio Therapeutics Unveils Preclinical Data On CLDN18.2 Program
17 Mar 2026 //
GLOBENEWSWIRE
Xilio Therapeutics Announces 1-For-14 Reverse Stock Split
12 Mar 2026 //
GLOBENEWSWIRE
Xilio Therapeutics Presents at Leerink Global Healthcare Conf
02 Mar 2026 //
GLOBENEWSWIRE
Xilio Therapeutics Grants Inducements Under Nasdaq Rules
02 Mar 2026 //
GLOBENEWSWIRE
Xilio Therapeutics Reveals Pipeline Progress & Q3 2025 Result
13 Nov 2025 //
GLOBENEWSWIRE
Xilio Highlights Differentiated Masked Immunotherapy Portfolio
07 Nov 2025 //
GLOBENEWSWIRE
Xilio Reports Late-Breaking Ph2 Vilastobart Data In MSS mCRC
07 Nov 2025 //
GLOBENEWSWIRE
Xilio Therapeutics Reveals Inducement Grants Per Nasdaq LR
03 Nov 2025 //
GLOBENEWSWIRE
Xilio Therapeutics To Showcase Vilastobart Phase 2 Data at SITC
30 Oct 2025 //
GLOBENEWSWIRE
Xilio Therapeutics To Present At (SITC) 40Th Annual Meeting
03 Oct 2025 //
GLOBENEWSWIRE
Xilio Therapeutics Reveals Inducement Grants Per Nasdaq LR
02 Oct 2025 //
GLOBENEWSWIRE
Xilio Starts Ph 2 XTX301 Trial, Hits $17.5M Gilead Milestone
09 Sep 2025 //
GLOBENEWSWIRE
Xilio Therapeutics Updates Pipeline, Business, Q2 2025 Financials
14 Aug 2025 //
GLOBENEWSWIRE
Xilio Therapeutics Inducement Grants Under Nasdaq LR 5635(c)(4)
01 Aug 2025 //
GLOBENEWSWIRE
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Rule
02 Jul 2025 //
GLOBENEWSWIRE
Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to Board
10 Jun 2025 //
GLOBENEWSWIRE
Xilio Therapeutics Closes $50.0M Public Offering
05 Jun 2025 //
GLOBENEWSWIRE
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Rule
03 Jun 2025 //
GLOBENEWSWIRE
Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart
31 May 2025 //
GLOBENEWSWIRE
Xilio Therapeutics Announces Pipeline, Business Updates, Q1 2025
08 May 2025 //
GLOBENEWSWIRE
Xilio Announces Inducement Grant Under Nasdaq LR 5635(c)(4)
02 May 2025 //
GLOBENEWSWIRE
Xilio Therapeutics to Present Ph 2 Data for Vilastobart at ASCO 2025
23 Apr 2025 //
GLOBENEWSWIRE
Xilio Announces Inducement Grants Under Nasdaq LR 5635(c)(4)
04 Apr 2025 //
GLOBENEWSWIRE
Xilio Therapeutics Updates Pipeline, Business, Q4, Full Year 2024
11 Mar 2025 //
GLOBENEWSWIRE
Xilio Therapeutics to Present at TD Cowen Health Care Conference
24 Feb 2025 //
GLOBENEWSWIRE
AbbVie Commits $2.1B to Revolutionary Tumor-Fighting Tech
13 Feb 2025 //
PRESS RELEASE
Xilio Therapeutics Announces Inducement Grants Under Nasdaq LR 5635
03 Feb 2025 //
GLOBENEWSWIRE
Xilio Announces Inducement Grant Under Nasdaq LR 5635(c)(4)
17 Jan 2025 //
GLOBENEWSWIRE
Xilio to Present Ph 2 Data for Vilastobart in Colorectal Cancer
19 Dec 2024 //
GLOBENEWSWIRE
Xilio Announces Inducement Grants Under Nasdaq LR 5635(c)(4)
03 Dec 2024 //
GLOBENEWSWIRE
Xilio Announces Phase 1C Data for Vilastobart in Solid Tumors
07 Nov 2024 //
GLOBENEWSWIRE
Xilio Therapeutics Presents XTX101 Data at SITC 39th Meeting
30 Oct 2024 //
GLOBENEWSWIRE
Xilio Therapeutics Announces Poster At SITC Annual Meeting
04 Oct 2024 //
GLOBENEWSWIRE
Xilio Announces Inducement Grants Under Nasdaq LR 5635(c)(4)
03 Oct 2024 //
GLOBENEWSWIRE
Xilio Therapeutics To Present At Morgan Stanley Healthcare Conference
28 Aug 2024 //
GLOBENEWSWIRE
Xilio Therapeutics Announces Q2 2024 Results And Pipeline Updates
08 Aug 2024 //
GLOBENEWSWIRE
Xilio Provides Pipeline Updates, Q1 2024 Financial Results
14 May 2024 //
GLOBENEWSWIRE
Xilio Announces Pipeline and Business Updates and Q4 and FY23 Financial Results
01 Apr 2024 //
GLOBENEWSWIRE
Xilio Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101
07 Dec 2023 //
GLOBENEWSWIRE
Xilio Announces Monotherapy Safety and Anti-Tumor Activity Data for XTX202
03 Nov 2023 //
GLOBENEWSWIRE
Xilio Therapeutics Announces Second Quarter 2023 Financial Results
14 Aug 2023 //
GLOBENEWSWIRE
Xilio Announces Preliminary Clinical Data from Phase 1 Trial of XTX101
25 May 2023 //
GLOBENEWSWIRE
